First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: USANA Health Sciences: the story is balanced — Active distributor count and retention rates in China/Hong Kong markets (typically 60-70% of Asia-Pacific revenue)
value - Deeply discounted valuation (0.4x P/S, 0.7x P/B, 2.7x EV/EBITDA) attracts contrarian value investors betting on stabilization…
Low direct sensitivity given zero debt and $0.1B cash generation, eliminating financing cost concerns.
Watch on earnings: USD/CNY exchange rate (DEXCHUS) given 70-75% Asia-Pacific revenue exposure and translation impacts, China consumer sentiment and retail sales trends as proxy for discretionary health spending in largest market, US consumer sentiment (UMCSENT) affecting North American distributor recruitment and product demand.
One Sentence Summary:
USANA Health Sciences: the story is balanced — active distributor count and retention rates in china/hong kong markets (typically 60-70% of asia-pacific revenue).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.